hPG80 Performances

A performing biomarker.

Present at all stages and for Multiple Cancer Types.

Last updated: August 3, 2020

1

Healthy Blood Donors vs All Combined Cancers 

Significant increase in hPG80 levels in all cancer patients (N= 1267, Median hPG80 = 4.77 pM) compared to healthy blood donors (N=557 for 18-70 yo, Median hPG80 = 1.05 pM and N=137 for 18-25 yo, Median hPG80 = 0.2 pM).

You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020

 

2

Diagnostic performances of hPG80 per Tumor types

Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. 

 

3

Performances of hPG80 vs Existing Tumor Markers

BREAST CANCER

  1. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer – A retrospective analysis of kinetics on 743 breast cancer patients. Stieber P et al., Clin Chim Acta., 2015. 

  2. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard,Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037.  

  3. N=53 patients. 

  4. N=9 patients, work ongoing.  

COLORECTAL CANCER

  1. CEA Monitoring in Colorectal Cancer. Fakih MG, Padmanabhan A., Oncology (Williston Park), 2006. Cutoff at 5 ng/mL. 

  2. Direct Comparison of Diagnostic Performance of 9 Quantitative Fecal Immunochemical Tests for Colorectal Cancer Screening. Gies A et al., Gastroenterology, 2018. 

  3. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. 

  4. N = 98 patients. 

  5. N = 192 patients.  

OVARIAN CANCER

  1. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Chen F et al., Cancer Manag Res, 2018.

  2. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037.  

  3. N = 27 patients.

  4. N = 181 patients.    

PROSTATE CANCER

  1. A review on the clinical Utility of PSA in Cancer Prostate. Adhyam M, Gupta AK; Indian J Surg Oncol, 2012. PSA cutoff at 4 ng/mL. 

  2. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, VéroniqueSaywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037.  

  3. N = 93 patients. 

  4. N = 444 patients.  

 

HEPATOCELLULAR CARCINOMA

  1. Serum tumor markers for detection of hepatocellular carcinoma. Zhou L et al., World J Gastroenterol., 2006. 

  2. Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037. 

  3. N = 27 patients. 

  4. N = 65 patients.  

hPG80 has a better sensitivity to detect HCC than AFP.

AFP was above 20ng/ml in 54.3% of the samples while hPG80 (circulating progastrin) was detected in 80.2% (threshold = 1pM).

Progastrin a new biomarker for hepatocellular cancer patient follow-up. Alexandre Prieur, Marie Dupuy, Pierre Liaud, Dominique Joubert and Eric Assenat. AACR 2019 - Poster #2222.

 

4

hPG80 for the monitoring of Minimal Residual Disease and Response to Treatment

PERITONEAL CARCINOMATOSIS

A cohort of patients with peritoneal involvements from gastrointestinal cancers, treated with peri-operative chemotherapy regimens and cytoreductive surgery (Lyon, France, NCT02823860). 

  • Global analysis. High levels of hPG80 before surgery. Decrease of hPG80 8h to 24h after surgery (From 3.08 pM to 1.57 pM; p=0.035).

  • Individual analysis. 74.2% of the patients had a decrease of at least 25% of hPG80 levels after surgery.

Sustained elevations in hPG80 concentrations after surgery could be suggestive of the presence of residual disease.

You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020 Gilles Freyer, Delphine Maucort-Boulch, Dominique Joubert and Olivier Glehen. ESMO 2018 - Poster # 1953.

PROSTATE CANCER

Elevated hPG80 levels in patients with advanced prostate cancer (aPCa)* (healthy blood donors 18 to 40 yo: median hPG80 = 0.37 pM vs aPCa: median hPG80 = 4.7 pM, p<0.0001).

*aPCa includes metastatic hormone sensitive (mHSPC) and metastatic castration resistant (mCRPC) prostate cancer patients.

Overall survival (OS) according to hPG80 levels evolution during follow-up. Patients with a serial increase of hPG80 had a worst overall survival compare to the other group (9.3 yo vs 12.4 yo, P = 0.019).

Plasma Progastrin Level As A Prognostic Biomarker In Advanced Prostate Cancer. Manish Kohli, Winston Tan, Léa Payen, Carole Langlois-Jacques, Pierre Liaud, Delphine Maucort-Boulch, Dominique Joubert and Alexandre Prieur. AACR 2019 - Poster #2294.

KIDNEY CANCER

Elevated hPG80 levels in patients with metastatic renal cell carcinoma (mRCC) (Cohort (healthy blood donors18-25 y/o): median hPG80 = 0.29 pM vs mRCC hPG80= 7.2 pM).

We compared hPG80 levels with the MSKCC prognostic criteria for patient survival. In this score, patients are separated in 3 groups: good, intermediate and poor prognostic. hPG80  levels were higher within the MSKCC score poor prognostic group (p<0.001) (median 30.39 pM vs 6 pM and 9.34 pM in the good and intermediate group, respectively).

hPG80 assay might be useful for defining subsets of mRCC patients with poor survival who need to be treated aggressively.

Prognostic Impact Of Progastrin Levels In Blood Compared To MSKCC Based Clinical Prognosis In Metastatic Renal Cell Cancer Patients. Manish Kohli, Winston Tan, Léa Payen, Carole Langlois-Jacques, Pierre Liaud, Delphine Maucort-Boulch, Dominique Joubert and Alexandre Prieur. AACR 2019 - Poster #2289. 

5

hPG80 for the Monitoring of Relapse (Tumor Activity)

MONITORING FOR HEPATOCELLULAR CARCINOMA RECURRENCE

Earlier detection of small lesions and the monitoring of recurrence may be improved with hPG80 as a supplemental blood-based biomarker, especially in AFP negative populations where there is limited information.

Patients in remission following disease management have lower hPG80 concentrations compared to active cancers.

76% of patients with progressing disease during or after treatment had an increased hPG80 > 25%.

Illustrative hPG80 longitudinal changes around and during disease management (baseline; remission; progression), with associated imaging obtained at the same times in a typical patient.

Progastrin a new biomarker for hepatocellular cancer patient follow-up. Alexandre Prieur, Marie Dupuy, Pierre Liaud, Dominique Joubert and Eric Assenat. AACR 2019 - Poster # 2222.

You B, Mercier F, Assenat E, et al : The oncogenic and druggable hPG80 is overexpressed in multiple cancers and detected in the blood of patients. EBioMedicine 51:102574, 2020.

MONITORING FOR OVARIAN CANCER RECURRENCE

70% of ovarian cancers are not diagnosed until stage III or IV where survival rates are low (48% after 5 years).  

As a result, cancer recurrence is high (70-95%) following standard treatment by surgery and combination chemotherapy.

hPG80, as a blood-based biomarker used in conjunction with CA125, could improve the early detection of residual disease, treatment efficacy, and/or relapse following treatment. 

Progastrin, a Novel Ubiquitous Cancer Blood Biomarker for Early Detection and Monitoring. Benoit You, Eric Assenat, Olivier Glehen, Delphine Maucort-Boulch, Léa Payen, Vahan Kepenekian, Marie Dupuy, Pierre Liaud, Thibault Mazard, Gwenaël Ferron, Maud Flacelière, Julien Soulé, Véronique Saywell, Fanny Belouin, Winston Tan, Laurent Villeneuve, Marc Ychou, Manish Kohli, Dominique Joubert and Alexandre Prieur. ASCO 2019 - Poster #3037.  

Learn more... 

about

hPG80

Main Scientific Publications
 

IT'S TIME TO CONTROL CANCER

It has been shown that hPG80 (Circulating Progastrin) is produced by all cancer cells across all stages, but in quantities 100 to 1000 times higher by cancer stem cells which are considered to be primarily responsible for recurrence and metastasis. 

hPG80 is released from the tumor and becomes detectable in the blood, making hPG80 the only blood biomarker that not only detects the presence but also the activity of the tumor.

16 different cancers have been tested, the 16 were positive. Of these 16 cancers, 11 have been published to date.

Detection and assay of hPG80 can provide Physicians with new information that can help them:

  • Evaluate treatment efficacy,

  • Monitor risk of relapse,

  • Assess Minimal Residual Disease (MRD) risk,

  • Diagnose cancers which have no biomarker and for at-risk populations, in order to detect early enough the tumor, easily located in these populations.

ECS-Progastrin is a subsidiary of Progastrine Invest SCSp (Cancer Control Funding Fund)  11 côte d'Eich, L1450, Luxemburg City - Grand Duchy of Luxemburg

MAINS LOCATIONS AND OFFICES:

  • LUXEMBURG

  • SWITZERLAND

  • FRANCE

  • UNITED ARAB EMIRATES

  • UNITED STATES OF AMERICA

MAINS COMPANIES:

  • ECS PROGASTRIN

  • ECS PROGASTRIN LAB

  • PROGASTRINE ET CANCERS

  • EUROBIODEV

  • PROGASTRIN MANUFACTURING

Progastrine Invest SCSp and its subsidiaries:

  • focus on innovation in cancer diagnosis, localization, follow-up and treatment,

  • hold the rights to the first hPG80 (Circulating Progastrin) assay which is now available,

  • hold the rights to the cancer therapy project with an anti-hPG80 antibody.

 

For ethical reasons and out of respect for practitioners, health institutions, populations and regulations in force in all countries where they operate, Progastrine Invest SCSp and its subsidiaries pay extreme attention to the information they publicly provide.

 

The management of Progastrine Invest SCSp subsidiaries and their scientific committee would like to remind you that only information published on the official communication media of the group's companies can be considered as confirmed and authorised.

© 2015-2020 ECS-Progastrin ® . All rights reserved